Avita is still burning cash and the road to profitability depends on clinical readouts for further indications over the next few years, with the use of RECELL currently limited to adult and paediatric ...

This study, which has enrolled 275 treatment-naïve patients, both with and without compensated cirrhosis, is designed to ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

In July, the FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette, or vaping, cessation, ...

with enrollment projected to complete this year and initial safety and molecular correlation data expected by year-end 2024 or early 2025. The LP-184 development program received a significant boost ...